Lilly new drug Galgality (galcanezumab-gnlm) achieves positive results in Phase 3 clinical trial IN CONQUER
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today,( http://announced positive results in theof thenew drug, http:// in theCONQUER of the Phase 3 ClinicalTrial(http://About Emgality
Emgality is a humanized CGRP monoclonal antibody that plays an important role in the onset of headachesBy binding to CGRP, it blocks CGRP from binding to its receptors, which is expected to relieve and improve headache symptomsIn September 2018, Emgality was approved by the U.SFDA(http://to prevent migraines in adultsAbout CONQUER
conquer is a Phase 3 phase 3 double-blind clinical trial in 12 countries The study included 462 patients with chronic (n?193,41.7%) or seizure migraines (n-269,58.2%), who had two to four different standard treatments for migraine prevention
drug (http:// failure to treat During the baseline period, patients had an average of 13.2 days of migraines per month After the screening period and the forward-looking baseline period, eligible patients were randomly assigned to the Emgality group or placebo group at a 1:1 scale for three months of double-blind treatment The study showed that patients treated with Emgality had a 4.1-day reduction in the number of migraine days per month, while those treated with a placebo had a 1.0-day reduction in the number of migraine days per month
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
